Neurophysins as tumor markers for small cell carcinoma of the lung: A cancer and leukemia group B evaluations
β Scribed by William G. North; J. Ware; L. H. Maurer; A. P. Chahinian; M. Perry
- Publisher
- John Wiley and Sons
- Year
- 1988
- Tongue
- English
- Weight
- 514 KB
- Volume
- 62
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Background. Small cell lung cancer (SCLC) is distinguished from other histologic types of lung cancer by possessing a variety of neuroendocrine properties. Neuron-specific enolase (NSE) is the most frequently elevated tumor marker for patients with SCLC at diagnosis. To assess the value of neural ce
## Abstract A phase II trial of etoposide and cisplatin for patients with previously treated small cell lung cancer was carried out by CALGB from June 1983 to May 1984. Thirtyβfive evaluable patients who had failed one prior chemotherapy regimen were treated with etoposide 80 mg/m^2^ and cisplatin
Five minor base ribonucleosides, primarily degradation products of transfer ribonucleic acid (tRNA), were evaluated as potential biological markers for patients with small cell carcinoma of the lung. The urinary concentration for pseudouridine, 1-methyladenosine, 1 -methylinosine, N2-methylguanosine